



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/648,557	08/25/2000	Christian Devaux	1017753-000152	5736
21839 7590 06/08/2010 BUCHANAN, INGERSOLL & ROONEY PC POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404				
EXAMINER				
PARKIN, JEFFREY S				
ART UNIT		PAPER NUMBER		
1648				
NOTIFICATION DATE		DELIVERY MODE		
06/08/2010		ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ADIPFDD@bipc.com
offserv@bipc.com

Received date: 12/28/2006

09648557 - 1548

Attorney's Docket No. 1017753-000152



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)

Christian DEVEAUX et al.)

Application No.: 09/648,557)

Filed: August 25, 2000)

For: INHIBITORS OF HIV REPLICATION)
AND METHOD OF TREATMENT OF)
HIV INFECTIONS)

Group Art Unit: 1648

Examiner: J. PARKIN

Confirmation No.: 5736

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c), the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: December 28, 2006

By: 

Deborah H. Yellin
Registration No. 45,904

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

12/29/2006 SZEWDIE1 00000070 09648557

01 FC:1806

160.00 0P

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //J.P./

Substitute for form 1449/PTO & 1449B/PTO

Complete if Known

SECOND
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(use as many sheets as necessary)

Sheet 1 of 1

Application Number	09/648,557
Filing Date	August 25, 2000
First Named Inventor	Christian DEVEA
Examiner Name	J. PARKIN
Attorney Docket No.	1017753-000152

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	VAN DER BURG et al., "HIV-1 Reverse Transcriptase-Specific CTL Against Conserved Epitopes Do Not Protect Against Progression to AIDS", The Journal of Immunology, 1997, 159: pgs. 3648-3654.

Examiner Signature	/Jeffrey Parkin/	Date Considered	05/30/2010
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./